Wei-Yu Kao
Overview
Explore the profile of Wei-Yu Kao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang Y, Lee J, Chen C, Kao W, Lin C, Yang S, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39981689
Background: Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct-acting antivirals (DAAs)-induced sustained virologic response (SVR) remains limited....
2.
Luo P, Chuang K, Ni C, Yeh H, Wu M, Hsieh Y, et al.
J Formos Med Assoc
. 2025 Jan;
PMID: 39794175
Purpose: To investigate the association of skeletal muscle mass and quality with survival outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with lenvatinib (LEN). Methods: In this retrospective study,...
3.
Su T, Yang S, Lee M, Kao W, Huang S, Chen F, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39761961
Background/aims: There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator...
4.
Lu C, Wang W, Li Y, Chang I, Chen C, Su C, et al.
Obes Surg
. 2024 Oct;
34(12):4393-4404.
PMID: 39448457
Purpose: Although noninvasive tests can be used to predict liver fibrosis, their accuracy is limited for patients with severe obesity and nonalcoholic fatty liver disease (NAFLD). We developed machine learning...
5.
Liu C, Cheng P, Fang Y, Chen C, Kao W, Lin C, et al.
J Hepatol
. 2024 Oct;
PMID: 39368711
Background & Aims: Data are limited on the risk of de novo hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) after achieving sustained virologic response at...
6.
Ho C, Fu C, Tan E, Kao W, Lee P, Huang Y, et al.
J Gastroenterol Hepatol
. 2024 Jun;
39(10):2077-2087.
PMID: 38864669
Background And Aim: The association between long-term proton-pump inhibitors (PPIs) use and malignancies had long been discussed, but it still lacks consensus. Our study investigated the association between PPI use...
7.
Liu C, Chang Y, Lee J, Chen C, Kao W, Lin C, et al.
J Med Virol
. 2024 May;
96(5):e29675.
PMID: 38746997
Early confirmation of sustained virologic response (SVR) or viral relapse after direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection is essential based on public health perspectives, particularly for patients...
8.
Jeong S, Liao Y, Tsai M, Wang Y, Wu I, Liu C, et al.
BMC Microbiol
. 2024 Apr;
24(1):139.
PMID: 38658841
Background: Gastric cancer is one of the global health concerns. A series of studies on the stomach have confirmed the role of the microbiome in shaping gastrointestinal diseases. Delineation of...
9.
Liu C, Chang Y, Fang Y, Cheng P, Chen C, Kao W, et al.
J Gastroenterol
. 2024 Apr;
59(7):609-620.
PMID: 38613690
Background: Information on the dynamics of metabolic dysfunction-associated steatotic liver disease (MASLD) among hepatitis C virus patients achieving sustained virologic response (SVR) with direct-acting antivirals (DAAs) is limited. Methods: We...
10.
Hsu S, Kao W, Huang Y
Asian J Surg
. 2023 Dec;
47(3):1472-1474.
PMID: 38092597
No abstract available.